Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1

Marvin T. Nieman, Mark Warnock, Ahmed A. K. Hasan, Fakhri Mahdi, Benedict R. Lucchesi, Nancy J. Brown, Laine J. Murphey and Alvin H. Schmaier
Journal of Pharmacology and Experimental Therapeutics November 2004, 311 (2) 492-501; DOI: https://doi.org/10.1124/jpet.104.069229
Marvin T. Nieman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Warnock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed A. K. Hasan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fakhri Mahdi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedict R. Lucchesi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy J. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laine J. Murphey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvin H. Schmaier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Thrombin and protease-activated receptor 1 (PAR1) activation antagonists were prepared based upon the peptide RPPGF, the angiotensin-converting enzyme breakdown product of bradykinin. A library of 72 peptides consisting of d and/or synthetic amino acids was designed with various substitutions in positions 1 to 5 in Arg-Pro-Pro-Gly-Phe (RPPGF). Two compounds, rOicPGF (TH146) and βAK2K-4(rOicPGF) (MAP4-TH146), were characterized further. TH146 or MAP4-TH146 completely inhibits threshold γ-thrombin-induced platelet aggregation at a concentration of 142 ± 0.05 or 19 ± 0.06 μM, respectively. TH146 completely inhibits threshold α-thrombin-induced washed platelet aggregation at 444 ± 0.04 μM. TH146 or MAP4-TH146 blocks 2 nM α-thrombin-induced fibroblast calcium mobilization with an IC50 value of 110 or 18 μM, respectively. Furthermore, significant prolongation of the activated partial thromboplastin time, prothrombin time, or thrombin clotting time occurs at 31, 62, or 7.8 μM TH146 and 0.4, 6.25, or 1.56 μM MAP4-TH146, respectively. TH146 and MAP4-TH146 inhibit both α-thrombin with a Ki value of 97 and 49 μM, respectively, and factor VIIa with a Ki value of 44 and 5 μM, respectively. Both TH146 and MAP4-TH146 specifically bind to the exodomain of recombinant PAR1. MAP4-TH146 (200 μM) completely blocks thrombocytin, a PAR1-activating snake venom protease, without inhibiting the enzyme's active site. TH146 inhibits γ-thrombin-induced aggregation of mouse platelets, prolongs mouse bleeding times, and delays the time to mouse carotid artery thrombosis. TH146 and MAP4-TH146 inhibit human and mouse platelet aggregation and mouse thrombosis. Analogs of RPPGF are model compounds to develop PAR1 activation antagonists as well as direct inhibitors to thrombin and factor VIIa.

Footnotes

  • This work was supported by Grant #1607 from the Michigan Economic Development Corporation and National Institutes of Health Grant HL61981 (to A.H.S.), HL04445 (to L.J.M.), and HL65193 (to N.J.B).

  • doi:10.1124/jpet.104.069229.

  • ABBREVIATIONS: PAR, protease-activated receptor; RPPGF, Arg-Pro-Pro-Gly-Phe; TH146, rOicPGF; MAP4-TH146, βAK2K4(rOicPGF); PRP, platelet-rich plasma; APTT, activated partial thromboplastin time; PT, prothrombin time; TCT, thrombin clotting time; FX, factor X; RWJ-58259, (αS)-N-[(1S)-3-amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrroli-dinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-difluorobenzenepropanamide.

    • Received March 30, 2004.
    • Accepted June 21, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 311 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 311, Issue 2
1 Nov 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1

Marvin T. Nieman, Mark Warnock, Ahmed A. K. Hasan, Fakhri Mahdi, Benedict R. Lucchesi, Nancy J. Brown, Laine J. Murphey and Alvin H. Schmaier
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 492-501; DOI: https://doi.org/10.1124/jpet.104.069229

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1

Marvin T. Nieman, Mark Warnock, Ahmed A. K. Hasan, Fakhri Mahdi, Benedict R. Lucchesi, Nancy J. Brown, Laine J. Murphey and Alvin H. Schmaier
Journal of Pharmacology and Experimental Therapeutics November 1, 2004, 311 (2) 492-501; DOI: https://doi.org/10.1124/jpet.104.069229
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin Synthesis in Red Blood Cells
  • Exosomal miRNAs drive thrombosis in COVID-19
  • mitochondrial miRs in Fabry disease
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics